| Schedule of the calculation of basic and diluted earnings per share |
The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended June 30, |
|
|
|
2025 |
|
2024 |
|
2023 |
Earnings per share – basic: |
|
|
|
|
|
|
|
|
|
|
Net earnings, including noncontrolling interest |
|
|
$ |
73,400 |
|
$ |
168,105 |
|
$ |
285,442 |
Less net earnings attributable to noncontrolling interest |
|
|
|
— |
|
|
— |
|
|
179 |
Net earnings attributable to Bio-Techne |
|
|
$ |
73,400 |
|
$ |
168,105 |
|
$ |
285,263 |
Income allocated to participating securities |
|
|
|
(37) |
|
|
(33) |
|
|
(70) |
Income available to common shareholders |
|
|
$ |
73,363 |
|
$ |
168,072 |
|
$ |
285,193 |
Weighted-average shares outstanding – basic |
|
|
|
157,521 |
|
|
157,708 |
|
|
157,179 |
Earnings per share – basic |
|
|
$ |
0.47 |
|
$ |
1.07 |
|
$ |
1.81 |
|
|
|
|
|
|
|
|
|
|
|
Earnings per share – diluted: |
|
|
|
|
|
|
|
|
|
|
Net earnings, including noncontrolling interest |
|
|
$ |
73,400 |
|
$ |
168,105 |
|
$ |
285,442 |
Less net earnings attributable to noncontrolling interest |
|
|
|
— |
|
|
— |
|
|
179 |
Net earnings attributable to Bio-Techne |
|
|
$ |
73,400 |
|
$ |
168,105 |
|
$ |
285,263 |
Income allocated to participating securities |
|
|
|
(37) |
|
|
(33) |
|
|
(70) |
Income available to common shareholders |
|
|
$ |
73,363 |
|
$ |
168,072 |
|
$ |
285,193 |
Weighted-average shares outstanding – basic |
|
|
|
157,521 |
|
|
157,708 |
|
|
157,179 |
Dilutive effect of stock options and restricted stock units |
|
|
|
2,196 |
|
|
3,066 |
|
|
4,676 |
Weighted-average common shares outstanding – diluted |
|
|
|
159,717 |
|
|
160,774 |
|
|
161,855 |
Earnings per share – diluted |
|
|
$ |
0.46 |
|
$ |
1.05 |
|
$ |
1.76 |
|